Study title:
Efficacy and safety of Symbicort® Turbuhaler® 160/4.5 ìg/inhalation, two inhalations twice daily plus as-needed, compared with Seretide™ Diskus™ 50/500 ìg/inhalation, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg/inhalation as-needed - a 6-month, randomised, double-blind, parallel-group, active-controlled, multi-national phase IIIB study in adult and adolescent patients with persistent asthma (AHEAD)
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Respiratory Tract Diseases [C08]
|
Brands: |
MAH holders: Please see report |
Assessment: |
Active substance: BUDESONIDE AND FORMOTEROL |
ATC code: |
Document link:
|
Document date:
|
Study number: D5890L00005 |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
Y
|